IRVINE, Calif., April 22 (UPI) -- Valeant Pharmaceuticals has offered to buy Allergan for at $45.7 billion in a cash and stock deal, in partnership with activist investor William Ackman.
The unlikely teaming up of Valeant and Allergan's single largest shareholder, will see Allergan's shareholders getting $48.30 in cash and and 0.83 percent in Valeant stock for each share they own, according to a Valeant statement today. Ackman-run Pershing Square Capital Management will support the offer.